Research

Found 142,651 articles

• Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot

  5/2/2023

  Science 37 Holdings, Inc., the industry-leading MetasiteTM, announced its partnership with the Digital Medicine Society in support of the CancerX inaugural project.

• NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study

  5/2/2023

   NeuroSense Therapeutics Ltd. today announced positive preliminary results from a novel biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Parkinson's disease (PD), the second most common neurodegenerative disorder.

• Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors

  5/2/2023

  Scorpion Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-478.

• Use of Medicines in the U.S. Continued to Grow in 2022 while Patient Out-of-Pocket Costs Remain Low, Says IQVIA Institute

  5/2/2023

  The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis.

• Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey

  5/2/2023

  Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked first in patient centricity, integrity, ease of relations and transparency in pricing by patient groups who worked with the company around the world.

• Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health

  5/2/2023

  Alloy Therapeutics, a biotechnology ecosystem company, announced it is collaborating with Lundbeck, a global pharmaceutical company specializing in brain diseases, in the discovery of novel biologics therapies.

• BrightPath Biotherapeutics and Artisan Bio Announce Research and Licensing Agreement to Accelerate Development of BrightPath's Novel Allogeneic iPSC Derived Cell Therapy Platform across Multiple Indications

  5/2/2023

  BrightPath Biotherapeutics Co., Ltd. (TYO: 4594) and Artisan Bio. Inc today announced they have signed a research and licensing agreement to accelerate BrightPath's next-generation iNKT cell therapies to clinic.

• Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma

  5/2/2023

  Halberd Corporation (OTC PINK:HALB) advances its pursuit toward pre-clinical testing of its patent-pending nasal spray.

• PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease

  5/2/2023

  PharmaTher Holdings Ltd. today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (“FDA”) for KETARX™ (ketamine) for the treatment for levodopa-induced dyskinesia in Parkinson’s disease (“LID-PD”).

• Ten63 Therapeutics Raises $15.9 Million in Oversubscribed Series A Financing to Drug the Undruggables by Combining the Power of AI and Physics-based Models

  5/2/2023

  Ten63 Therapeutics, a company combining generative AI and physics-based models to develop first- and best-in-class therapeutics, today announced the closing of an oversubscribed $15.9 million Series A financing led by new investor Hatteras Venture Partners.

• Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors

  5/2/2023

  Hygieia is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.

• Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

  5/2/2023

  Lantern Pharma Inc. today announced that it has developed highly-accurate and industry-leading AI algorithms to predict the ability of a drug or compound to pass the blood-brain-barrier (BBB), a highly selective border that can prevent drugs from entering brain tissues.

• Anavo Therapeutics extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic

  5/2/2023

  Anavo Therapeutics announced today an EUR 8.5 million seed round extension, adding MRL Ventures Fund as a new investor. All existing investors, M Ventures, INKEF, Taiho Ventures, and Bioqube Ventures, participated in the extension, bringing the total seed round to EUR 28 million.

• New Family Heart Foundation Study Reveals Systemic Underdiagnosis and Undertreatment of Homozygous Familial Hypercholesterolemia

  5/2/2023

  A new study from the Family Heart Foundation, a leading research and advocacy organization, showed the diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) is delayed, and often occurs after a heart attack or early atherosclerotic cardiovascular disease (ASCVD).

• SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation

  5/2/2023

  SciSparc Ltd today announced that the last patient enrolled in the Company's Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (“AD”) and agitation, completed its treatment.

• BostonGene and Australia’s Mater Research Collaborate in New Follicular Lymphoma Study

  5/2/2023

  BostonGene Corporation has announced a major research collaboration with Australia’s Mater Research to discover novel diagnostic biomarkers of follicular lymphoma and ultimately improve treatment for patients in the advanced stages of the disease.

• Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

  5/2/2023

  Can-Fite BioPharma Ltd. today announced that it discovered the mechanism of action (MOA) involved with the significant anti-cancer effect of Namodenoson in pancreatic carcinoma. Namodenoson de-regulates the Wnt signal transduction pathway, a key modulator of pancreatic carcinoma cell growth.

• Teleflex Launches New Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet in the United States

  5/2/2023

  Teleflex Incorporated today announced the launch of two new devices designed to enhance PICC insertion procedures and reduce the chance of complications.

• Miach Orthopaedics Launches BEAR® Implant Registry Study

  5/2/2023

  Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue restoration, announced initiation of the Bridge Registry Post-Market Study of the company’s Bridge-Enhanced ACL Restoration Implant for anterior cruciate ligament tears.

• BioCentriq and panCELLa execute research agreement to study stem cell-derived Natural Killer cell expansion technology

  5/2/2023

  BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa's genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells.